AIM: To evaluate the costs and survival estimates of metastatic colorectal carcinoma patients treated with conventional cytostatic protocols and adjuvant monoclonal antibodies (mAbs). METHODS: Retrospective randomized case series and cost-of-illness analysis was used. Metastatic colorectal carcinoma cases (62) were randomly selected from the archive of the largest university military hospital in Southeastern Europe. RESULTS: A 6-month longer survival was attributed to mAbs (p = 0.581). Conventional protocols incurred € 5137 (95% CI: € 3758-€ 6517) versus € 22,113 (95% CI: € 16,201-€ 28,025) total direct medical costs in mAb-based group. ICER of € 32,108 per life year gained attributable to mAbs three-fold exceeded informal willingness to pay threshold of Serbia. CONCLUSION: mAbs adjuvant protocols had modest positive impact on 5-year survival rates. Costs were driven by targeted biologicals, but significantly higher costs of care were recorded in mAb-treated group in other domains, as well. More selective prescription and reimbursement criteria should be applied to increase cost-effectiveness of targeted oncology agents.
AIM: To evaluate the costs and survival estimates of metastatic colorectal carcinomapatients treated with conventional cytostatic protocols and adjuvant monoclonal antibodies (mAbs). METHODS: Retrospective randomized case series and cost-of-illness analysis was used. Metastatic colorectal carcinoma cases (62) were randomly selected from the archive of the largest university military hospital in Southeastern Europe. RESULTS: A 6-month longer survival was attributed to mAbs (p = 0.581). Conventional protocols incurred € 5137 (95% CI: € 3758-€ 6517) versus € 22,113 (95% CI: € 16,201-€ 28,025) total direct medical costs in mAb-based group. ICER of € 32,108 per life year gained attributable to mAbs three-fold exceeded informal willingness to pay threshold of Serbia. CONCLUSION: mAbs adjuvant protocols had modest positive impact on 5-year survival rates. Costs were driven by targeted biologicals, but significantly higher costs of care were recorded in mAb-treated group in other domains, as well. More selective prescription and reimbursement criteria should be applied to increase cost-effectiveness of targeted oncology agents.
Authors: Tomasz Holecki; Maria Węgrzyn; Aldona Frączkiewicz-Wronka; Karolina Sobczyk Journal: Int J Environ Res Public Health Date: 2020-04-20 Impact factor: 3.390
Authors: Noha Rashad; Mohamed Abdulla; Mohamed Farouk; Yasser Elkerm; Salem Eid Salem; Maha Yahia; Amr S Saad; Ahmed Hassan Abdel Aziz; Ghada Refaat; Ibrahim Awad; Maha ElNaggar; Khaled Kamal; Basel Refky; Mohamed Abdelkhalek; Ahmed Touny; Loay Kassem; Emad Shash; Abdelhay A Abdelhay; Bahaa Eldin Mahmoud; Karima Oualla; Nesrine Chraiet; Hussein AwadElkarim H Maki; Yasser Abdel Kader Journal: Cancer Manag Res Date: 2022-02-28 Impact factor: 3.989